Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 1998

View Archived Issues

Company Profile: AdProTech

Phytera and Galileo enter into collaborative agreement

Rhone-Poulenc Rorer expands licensing agreement with Enzon for Oncaspar

CombiChem achieves milestone in Roche Bioscience collaboration

Maxim's mucosal vaccine research published

The Liposome Company: Q1 1998 highlights

Oxygent research agreement restructured

SciClone and Schering-Plough begin phase III trial of Zadaxin in Japan

Neurocrine Biosciences: Q1 1998 highlights

Merck characterizes new orally bioavailable thrombin inhibitor: L-374087

Ondansetron suppresses spontaneous sleep apnea in rats

Muse approved in Sweden

Barr receives FDA approval for generic form of ReVia

Rhone-Poulenc Rorer submits NDA for ebastine in U.S.

Oncogene Science Diagnostics and Fujirebio form cancer diagnostics collaboration

Another market introduction for Xalatan

SU-5416 advances to phase I/II trials in Kaposi's sarcoma

MRI with alpha(v)/beta(3)-targeted MAb as a method of detecting tumor angiogenesis

Recombinant antithrombin III pivotal clinical trials begin

AtheroGenics receives FDA approval to begin AGI-1067 trial

Unimed discontinues U.S. registration process for nitazoxanide indication

FDA advisory committee recommends approval of Thyrogen

European Commission approves Novartis' Exelon

U.S. patent issues for ImClone Systems' flk-1/KDR receptor-targeting antibodies

Scios and Janssen to copromote Risperdal

Palatin finalizes license for erectile dysfunction product

Mechanism of antitumor activity of clotrimazole identified

Zonagen, Schering AG to drop contraceptive vaccine collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...